Sanofi Ends Nurix STAT6 Degrader Trial
The discontinued SAR448272 was in Phase 1 testing, so the program never reached patients and removes one candidate from the degrader pipeline.
Updated on Nov. 3, 2026 in Biotech
Sanofi has discontinued the Phase 1 first-in-human trial of SAR448272, an oral STAT6 degrader, and terminated the program, Nurix Therapeutics announced on November 3, 2026. The development was in clinical testing, not approved, and has now been stopped.
Why it matters
The termination removes one candidate from the STAT6 degrader pipeline, a class of drugs designed to use E3 ligases to tag and clear the STAT6 protein. It arrives as Nurix's other programs continue, showing that early-stage clinical attrition remains a routine feature of this drug-discovery approach.
The disclosure reports the trial status and a cash balance but no efficacy, safety, or dosing data for SAR448272. The only measured figure is the $1.1 billion liquidity position, which Nurix ties to a runway into 2029.
The players
Nurix Therapeutics
A Brisbane, California biotechnology company whose DEL-AI platform discovers protein-degrading agents that use E3 ligases, with programs including bexobrutideg in Phase 3 for chronic lymphocytic leukemia.
Sanofi
A global pharmaceutical company that licensed Nurix's degrader programs under a 2019 collaboration and made the decision to end the SAR448272 trial.
Gilead
A biopharmaceutical company that partners with Nurix on GS-6791/NX-0479, which is in Phase 1 trials.
The details
SAR448272 is a small molecule designed as a degrader, meaning it recruits the cell's own E3 ligase enzymes to tag a target protein for destruction rather than merely blocking it. Nurix built its DEL-AI drug discovery platform to find such agents under a 2019 collaboration with Sanofi. Because SAR448272 is taken orally, it was being tested as a pill rather than an injection. Sanofi's decision ends clinical testing of this candidate, and Nurix does not expect milestone payments or royalties from it.
Timeline
2019: Nurix and Sanofi signed their collaboration agreement.
2025: Sanofi exercised a license extension option for two programs.
August 31, 2026: Nurix's cash balance of $1.1 billion was measured.
November 3, 2026: Nurix announced Sanofi's decision to discontinue SAR448272.
Second half of 2029: Nurix's projected end of funded operations.
The Tech Race
Nurix's remaining programs, including bexobrutideg in Phase 3 and NX-1607 in multiple Phase 1b cohorts, now carry the company's clinical story. The Gilead-partnered GS-6791/NX-0479 in Phase 1 is the other active degrader program named in the source.
Patients are not affected directly because SAR448272 was still in first-in-human testing and was never available outside a trial. Any future STAT6 degrader would need to clear the trial stages that this candidate did not complete.
The takeaway
Early-stage terminations like this one show that a platform's promise is tested one candidate at a time. Watch for Sanofi's decisions on its remaining licensed programs, and for Nurix's next clinical readouts from bexobrutideg and NX-1607.
Further reading
For the broader scientific context, explore the Biotech coverage on how targeted protein degradation is moving through clinical development.
